U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when combined with LAZCLUZE® (lazertinib)
Leader of Transnational Terrorist Group Sentenced to 30 Years in Prison for Soliciting Hate Crimes and Murder, and Conspiring to Provide Material Support to Terrorists
Federal Reserve Board withdraws 2023 policy statement and issues new policy statement regarding the treatment of certain Board-supervised banks that facilitates responsible innovation
Voters Give Democrats In Congress A Record Low Job Approval But Still Might Vote For Them In 2026, Quinnipiac University National Poll Finds; Majority Think Trump's Use Of Presidential Power Goes Too Far
KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free Survival, Overall Survival and Pathologic Complete Response Rates for Cisplatin-Eligible Patients with MIBC When Given Before and After Surgery